Full text loading...
薬理と治療
Abstract
Sake lees are obtained as a by−product in a manufacturing process of the liquor made from rice. It’s confirmed that several peptides obtained by treatment of sake lees with protease have an angiotensinI−converting enzyme inhibitor(ACE−I)activity. We investigated the hypotensive effects and safety of rice peptide in a placebo controlled single−blind study. 38 volunteers(male/female=21/17)with high−normal blood pressure, mild hypertension or moderate hypertension untreated with drugs. The rice peptide group(male/female=11/8, mean age 51 years, SBP/DBP=148.9±16.0 mmHg/92.9±7.8 mmHg)was given the test capsule containing 600 mg rice peptide(1000 mg as a material), and the control group(male/female=10/9, mean age 48 years, SBP/DBP=143.4±11.5 mmHg/92.1±7.9 mmHg) was given the placebo capsule, over a period of 12 weeks. The results revealed that the SBP was significantly reduced at 4, 8, 12 weeks(SBP/DBP=140.8±14.7 mmHg/88.2±10.1 mmHg)in the rice peptide group, but it was not significantly lower versus placebo group. And the pulse wave velocity(PWV)was a significant fluctuation to 1499.2±266.8(cm/s)from 1562.0±340.5(cm/s)in the rice peptide group. In addition, no adverse event and no marked changes were observed in pulse rate, blood indexes, urinalysis, and physical examination. These results suggest that the rice peptide moderately reduces the blood pressure in subjects with high−normal blood pressure, mild hypertension or moderate hypertension and that it is also very safe.(Jpn Pharmacol Ther 2008;36:517−29)KEY WORDS Rice peptide, Hypertension, PWV(pulse wave velocity), ACE−I
Data & Media loading...